Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown
1. Denmark reduced its growth forecast due to weaker expectations for Novo Nordisk. 2. U.S. exports of Danish pharmaceuticals fell, affecting Novo's market share. 3. Increased competition and generic medicines challenge Novo in the weight loss market. 4. U.S. tariffs have pressured the pharmaceutical sector and GDP growth expectations. 5. Despite forecasts, Denmark's economy remains strong with low inflation and high employment.